| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Aejaz Nasir | |
| Pamela Hodul | |||
| Larry Kvols | |||
| Jonathan R Strosberg | |||
| P2860 | cites work | Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis | Q21145267 |
| Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas | Q24544397 | ||
| Islet cell tumor and a syndrome of refractory watery diarrhea and hypokalemia | Q28183532 | ||
| Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner | Q28184844 | ||
| The chromogranin-secretogranin family | Q28185052 | ||
| Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34 | Q28245141 | ||
| Necrolytic migratory erythema with carcinoma of the pancreas | Q28245618 | ||
| Identification and characterization of the tuberous sclerosis gene on chromosome 16 | Q28257738 | ||
| Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system | Q28262479 | ||
| Molecular pathology of the MEN1 gene | Q28262579 | ||
| Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry | Q31994867 | ||
| Radiofrequency ablation of neuroendocrine liver metastases: the Middlesex experience | Q33212716 | ||
| Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms | Q33373397 | ||
| Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome | Q33501070 | ||
| Detailed genetic mapping of the von Hippel-Lindau disease tumour suppressor gene | Q33594951 | ||
| Somatostatin receptor scintigraphy in gastrinomas. | Q33798780 | ||
| The biological characteristics of chromogranin A and its role as a circulating marker in neuroendocrine tumours | Q33813771 | ||
| Tumor markers in neuroendocrine tumors | Q34001693 | ||
| Are patients with multiple endocrine neoplasia type I prone to premature death? | Q34064454 | ||
| Guidelines for diagnosis and therapy of MEN type 1 and type 2. | Q34104591 | ||
| Liver transplantation for metastatic neuroendocrine tumors | Q73256758 | ||
| Genotype/phenotype correlation of multiple endocrine neoplasia type 1 gene mutations in sporadic gastrinomas | Q73351512 | ||
| Zollinger-Ellison syndrome. Clinical presentation in 261 patients | Q73360415 | ||
| Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and | Q73482984 | ||
| p53 and proliferating cell nuclear antigen in endocrine tumors of pancreas and intestinal carcinoids | Q73488967 | ||
| The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids: importance of histologic grading, MIB-1, p53, and bcl-2 immunoreactivity | Q73624230 | ||
| Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center | Q73694656 | ||
| Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use | Q73697718 | ||
| Analysis of the retinoblastoma tumour suppressor gene in pancreatic endocrine tumours | Q74025186 | ||
| Chromosomal alterations in human pancreatic endocrine tumors | Q74082553 | ||
| Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors | Q74163966 | ||
| Expression of vascular endothelial growth factor in digestive neuroendocrine tumours | Q74447035 | ||
| Midgut Carcinoids and Solid Carcinomas of the Intestine: Differences in Endocrine Markers and p53 Mutations | Q74454218 | ||
| Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system | Q74561633 | ||
| Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden | Q74610168 | ||
| Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome | Q74611871 | ||
| Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? | Q74770146 | ||
| Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both | Q74817194 | ||
| The classification of carcinoid tum ours | Q76405787 | ||
| THE CARCINOID CRISIS | Q76839195 | ||
| Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid | Q77101570 | ||
| Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden | Q77357641 | ||
| Genomic imbalances in the progression of endocrine pancreatic tumors | Q77361239 | ||
| Vasoactive intestinal polypeptide secreting islet cell tumors: a 15-year experience and review of the literature | Q77687435 | ||
| Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors | Q78176560 | ||
| Classification of low-grade neuroendocrine tumors of midgut and unknown origin | Q78582056 | ||
| Life history of the carcinoid tumor of the small intestine | Q79075369 | ||
| Aggressive surgery for metastatic liver neuroendocrine tumors | Q79359618 | ||
| Medical treatment of benign insulinoma using octreotide LAR: a case report | Q79379722 | ||
| Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center | Q80110878 | ||
| Circulating levels of angiogenic cytokines can predict tumour progression and prognosis in neuroendocrine carcinomas | Q81609310 | ||
| Neuroendocrine hepatic metastases: does aggressive management improve survival? | Q81681815 | ||
| Gastric carcinoid associated with the syndrome of hypergastrinemic atrophic gastritis. A prospective analysis of 11 cases | Q42523039 | ||
| Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors | Q42600774 | ||
| Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide | Q43611319 | ||
| Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide | Q43676725 | ||
| Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. | Q43754199 | ||
| [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients | Q43755514 | ||
| Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial | Q43787521 | ||
| Control of carcinoid syndrome with hepatic artery embolization | Q43840133 | ||
| Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin--alone or in combination with 5-FU. | Q43908209 | ||
| Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors | Q43923598 | ||
| Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience | Q43966902 | ||
| Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies | Q43966904 | ||
| Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. | Q43982599 | ||
| Indications and results of liver transplantation in patients with neuroendocrine tumors | Q43997377 | ||
| Rectal and colonic carcinoids. A clinicopathologic study of 84 cases | Q44131024 | ||
| Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results | Q44409339 | ||
| Substance P secretion by carcinoid tumours | Q44482479 | ||
| Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival | Q44494869 | ||
| Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience | Q44580157 | ||
| Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas | Q44582807 | ||
| A retrospective analysis of 1570 appendiceal carcinoids | Q44607152 | ||
| Benign and malignant gastrinoma | Q44802213 | ||
| CARCINOID TUMORS OF THE RECTUM. | Q44971630 | ||
| Flushing in the carcinoid syndrome and plasma kallikrein | Q45189471 | ||
| Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate | Q45226553 | ||
| Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors | Q46443851 | ||
| Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. | Q46477657 | ||
| Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. | Q46624741 | ||
| Carcinoid TumorsAn analysis of 2837 cases | Q46711683 | ||
| Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b | Q46716129 | ||
| Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors | Q46900223 | ||
| Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors | Q46975692 | ||
| Effect of multiple endocrine neoplasia type 1 (MEN1) gene mutations on premature mortality in familial MEN1 syndrome with founder mutations | Q47232369 | ||
| Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients | Q47900511 | ||
| Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma | Q48100816 | ||
| Karnofsky memorial lecture. An odyssey in the land of small tumors | Q48529866 | ||
| Purification and characterization of human neuron-specific enolase: radioimmunoassay development. | Q50925218 | ||
| Glucose-responsive and octreotide-sensitive insulinoma. | Q51498065 | ||
| Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. | Q51600743 | ||
| Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. | Q51623701 | ||
| Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment. | Q51767041 | ||
| Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. | Q52973188 | ||
| Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. | Q53537770 | ||
| Identification of enteramine, the specific hormone of the enterochromaffin cell system, as 5-hydroxytryptamine. | Q55038163 | ||
| Treatment of type II gastric carcinoid tumors with somatostatin analogues | Q57009668 | ||
| Carcinoid tumor of the appendix: treatment and prognosis | Q57650356 | ||
| Somatostatin Receptors in the Diagnosis and Therapy of Neuroendocrine Tumor | Q58354262 | ||
| Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide | Q58354272 | ||
| Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma | Q60685897 | ||
| Resection versus transplantation for liver metastases from neuroendocrine tumors | Q61623028 | ||
| Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. | Q34131025 | ||
| A 5-decade analysis of 13,715 carcinoid tumors | Q34175374 | ||
| Antiproliferative effect of somatostatin and analogs | Q34199306 | ||
| Genetic aspects of adenomatosis of endocrine glands | Q34234754 | ||
| Metastatic carcinoid tumors and the carcinoid syndrome. A selective review of chemotherapy and hormonal therapy | Q34391132 | ||
| Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours | Q34409477 | ||
| Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients | Q34410241 | ||
| Carcinoid tumours. Frequency in a defined population during a 12-year period | Q34470534 | ||
| Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors | Q34498450 | ||
| Malignant pancreatic tumour within the spectrum of tuberous sclerosis complex in childhood | Q34503083 | ||
| Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors | Q34552576 | ||
| Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients | Q34729926 | ||
| Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract | Q35020349 | ||
| Hepatic surgery for metastases from neuroendocrine tumors | Q35123026 | ||
| Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation | Q35363122 | ||
| Synaptophysin: a marker protein for neuroendocrine cells and neoplasms | Q35606412 | ||
| Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization | Q35787979 | ||
| Updated population-based review of carcinoid tumors | Q35814978 | ||
| Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease. | Q35832622 | ||
| TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. | Q35837124 | ||
| Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids | Q35842172 | ||
| Ablative therapies for liver metastases of gastroenteropancreatic endocrine tumors | Q35915022 | ||
| Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion | Q35939961 | ||
| Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. | Q36011278 | ||
| Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract | Q36047418 | ||
| Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome | Q36085109 | ||
| Endocrine tumours of the pancreas | Q36299166 | ||
| The molecular genetics of gastroenteropancreatic neuroendocrine tumors | Q36301318 | ||
| Somatostatin and Analogues in the Treatment of Cancer | Q36485625 | ||
| Preoperative detection of gastrointestinal neuroendocrine tumors using endoscopic ultrasonography. | Q36696878 | ||
| Mammalian target of rapamycin: master regulator of cell growth in the nervous system | Q36822152 | ||
| Therapeutic considerations for the malignant carcinoid syndrome | Q38656942 | ||
| Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors | Q39342724 | ||
| Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors | Q39354234 | ||
| Liver transplantation for treatment of metastatic neuroendocrine tumors | Q39380441 | ||
| Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes | Q39390316 | ||
| Liver transplantation for metastatic neuroendocrine carcinoma: an analysis of 103 patients | Q39443075 | ||
| Somatostatin and analogues in the treatment of VIPoma | Q39468694 | ||
| A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study | Q39483669 | ||
| The management of patients with advanced carcinoid tumors and islet cell carcinomas | Q39486669 | ||
| Transcatheter chemoembolization of progressive carcinoid liver metastasis | Q39490259 | ||
| VIPoma syndrome | Q39509595 | ||
| Cytoreductive hepatic surgery for neuroendocrine tumors | Q39513967 | ||
| Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results | Q39541499 | ||
| Insulinoma: clinical and diagnostic features of 60 consecutive cases | Q39585623 | ||
| Zollinger-Ellison syndrome. Current concepts in diagnosis and management | Q39670873 | ||
| The syndrome of type A chronic atrophic gastritis, pernicious anemia, and multiple gastric carcinoids. | Q39732130 | ||
| Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five-year appraisal | Q40121934 | ||
| Rectal carcinoid tumors--treatment and prognosis | Q40231931 | ||
| Insulin-like growth factor 1 signaling in human gastrointestinal carcinoid tumor cells. | Q40469407 | ||
| The somatostatin receptor family. | Q40482710 | ||
| Revised classification of neuroendocrine tumours of the lung, pancreas and gut | Q40494318 | ||
| Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization | Q40523698 | ||
| Diagnosis and treatment of pancreatic neuroendocrine tumors | Q40549142 | ||
| Frequent overexpression of cyclin D1 in sporadic pancreatic endocrine tumours | Q40557717 | ||
| WDHA (watery diarrhea, hypokalemia, achlorhydria) syndrome: clinical features, diagnosis, and treatment | Q40566771 | ||
| Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors | Q40581977 | ||
| Somatostatin analogs for diagnosis and treatment of cancer | Q40624010 | ||
| Metastatic carcinoid tumors and the malignant carcinoid syndrome | Q40642546 | ||
| Carcinoids of the rectum | Q40679926 | ||
| Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. | Q40718905 | ||
| Octreotide | Q40929319 | ||
| Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. | Q40951627 | ||
| Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum | Q41004578 | ||
| Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). | Q41345043 | ||
| Gastrointestinal endocrine tumours. Gastrinoma | Q41439948 | ||
| Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action | Q41508955 | ||
| Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth | Q41661319 | ||
| Establishment and characterization of a human carcinoid in nude mice and effect of various agents on tumor growth | Q41670024 | ||
| Surgery to cure the Zollinger-Ellison syndrome | Q41686955 | ||
| Anesthesia for patients with carcinoid syndrome | Q41691043 | ||
| Imaging advances in the diagnosis of endocrine neoplasia | Q41702438 | ||
| Functioning Insulinoma—Incidence, Recurrence, and Long-Term Survival of Patients: A 60-Year Study | Q41789411 | ||
| Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors | Q42487585 | ||
| Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells | Q42492773 | ||
| Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. | Q42500055 | ||
| Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal o | Q42504190 | ||
| Prognosis of Carcinoid Heart Disease | Q61648559 | ||
| Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study | Q61852957 | ||
| Pancreatic involvement in von Hippel–Lindau disease | Q62929393 | ||
| Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma | Q67485775 | ||
| Localization of Pancreatic Endocrine Tumors by Endoscopic Ultrasonography | Q67488911 | ||
| Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study | Q67507449 | ||
| Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide | Q67881444 | ||
| Influence of a serotonin- and dopamine-rich diet on platelet serotonin content and urinary excretion of biogenic amines and their metabolites | Q67899414 | ||
| Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy | Q68079130 | ||
| Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome | Q68084123 | ||
| A glucagon-secreting alpha-cell carcinoma of the pancreas | Q68558410 | ||
| Detection of duodenal gastrinomas by operative endoscopic transillumination. A prospective study | Q68582798 | ||
| Cholera-like syndrome and pancreatic islet cell tumors | Q68610882 | ||
| Carcinoid tumours of the appendix are different | Q68642131 | ||
| Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue | Q68972347 | ||
| Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities | Q69015529 | ||
| Familial Occurrence of Metastasizing Carcinoid Tumors | Q69498316 | ||
| Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995 | Q69882499 | ||
| Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995) | Q69902412 | ||
| Carcinoid tumors of the vermiform appendix | Q69974691 | ||
| Vasoactive intestinal peptide and watery-diarrhoea syndrome | Q69998199 | ||
| Increased dopamine production in patients with carcinoid tumors | Q70063394 | ||
| Prostaglandins in amine-peptide-secreting tumours | Q70096626 | ||
| Secretion of chromogranin A by peptide-producing endocrine neoplasms | Q70135399 | ||
| Morphology and pathogenesis of endocrine hyperplasias, precarcinoid lesions, and carcinoids arising in chronic atrophic gastritis | Q70172568 | ||
| Pancreatic endocrine tumors | Q70338362 | ||
| C-peptide during the prolonged fast in insulinoma | Q70589789 | ||
| The glucagonoma syndrome. Clinical and pathologic features in 21 patients | Q71013712 | ||
| Carcinoid tumors of the appendix | Q71124156 | ||
| Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography | Q71974455 | ||
| Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon | Q72086248 | ||
| Clinical Management of Gastric Carcinoid Tumors | Q72114601 | ||
| Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study | Q72250861 | ||
| Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients | Q72359921 | ||
| Hepatic resection for metastatic neuroendocrine carcinomas | Q72400702 | ||
| Comparison of mutations of ras oncogene in human pancreatic exocrine and endocrine tumors | Q72536886 | ||
| Somatostatin | Q72567894 | ||
| Gastric carcinoids. The Yale Experience | Q72624766 | ||
| Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation | Q72668023 | ||
| Prognostic variables in patients with gastrointestinal carcinoid tumours | Q72707069 | ||
| Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up | Q72729791 | ||
| Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor | Q72828149 | ||
| Liver transplantation for hepatic metastases of neuroendocrine tumors | Q72853207 | ||
| Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma | Q72866285 | ||
| Intraarterial calcium stimulation test for detection of insulinomas | Q72906001 | ||
| Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features | Q73046468 | ||
| The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors | Q73234104 | ||
| Zollinger-Ellison Syndrome | Q73246576 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 113-125 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Gastrointestinal cancer research : GCR | Q27722152 |
| P1476 | title | Biology and treatment of metastatic gastrointestinal neuroendocrine tumors | |
| P478 | volume | 2 |
| Q36027379 | A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors |
| Q35128224 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors |
| Q37454406 | Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors |
| Q37085554 | Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database. |
| Q33936290 | Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study |
| Q90693879 | Current Practices and Novel Techniques in the Diagnosis and Management of Neuroendocrine Tumors of Unknown Primary |
| Q42036384 | Dipeptidyl Peptidase-4 Inhibition May Stimulate Progression of Carcinoid Tumor |
| Q42017845 | Duodenal neuroendocrine tumor and the onset of severe diabetes mellitus in a US veteran |
| Q34121507 | Elevated cleaved caspase-3 is associated with shortened overall survival in several cancer types |
| Q38124702 | Evolving treatment strategies for management of carcinoid tumors |
| Q21198838 | Hepatic arterial embolization in patients with neuroendocrine tumors |
| Q34121523 | Lin28B is a novel prognostic marker in gastric adenocarcinoma. |
| Q92486877 | Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors |
| Q34528199 | Multimodal management of neuroendocrine liver metastases. |
| Q41962477 | Neuroendocrine tumors: is there a standard treatment? |
| Q46534024 | Overexpression of Nanog protein is associated with poor prognosis in gastric adenocarcinoma |
| Q90751316 | Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an |
| Q38845060 | Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. |
| Q59304712 | Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I |
| Q28078610 | Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? |
| Q92529055 | Synchronous NET and colorectal cancer development: a case report |
| Q36347272 | The expanding role of somatostatin analogs in the management of neuroendocrine tumors. |
| Q26740374 | The pivotal role of mammalian target of rapamycin inhibition in the treatment of patients with neuroendocrine tumors |
| Q92513237 | Tumor Lysis Syndrome after Hepatic Artery Embolization in a Patient with Neuroendocrine Tumor of Unknown Primary |
| Q24321056 | Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration |
| Q82270601 | Vasculogenic mimicry: a new prognostic sign of gastric adenocarcinoma |
| Q54456530 | [Advanced research of mTOR and lung carcinoid tumors]. |
Search more.